trial · primary record
Autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes
B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma
| Phase | Phase 1 |
|---|---|
| Status | ACTIVE |
| Sponsor | Unknown |
| Enrolment | 37 |
| Primary completion | 2027-08-11 |
| Primary endpoint | Toxicity profile of T-cell infusion as defined by all toxicities associated with T cells at the probably or definite levels |
| Registry ID | NCT02153580 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T02:32:11.078Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT02153580
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.